Medeloop is an AI-powered clinical research platform building an operating system for medical evidence - from grant discovery to real-world evidence generation to point-of-care intelligence. Founded by former surgeon Dr. Rene Caissie, the San Francisco company uses agentic AI to automate biostatistics, study monitoring, and protocol compliance for academic medical centers, health systems, and pharma.
Unlearn.AI is a San Francisco biotech-AI company that builds disease-specific machine learning models to generate digital twins of clinical trial participants - longitudinal predictions of how each patient would have fared on placebo. Folded into a statistical method called PROCOVA and a trial design called TwinRCT, the approach lets sponsors shrink control arms by up to a third, so more patients receive the experimental drug while trials reach answers faster. Founded in 2017 by physicists Charles Fisher, Aaron Smith and Jon Walsh, the company has raised about $130M and earned a first-of-its-kind EMA qualification for an AI-based method to reduce sample size in pivotal trials.
PatientIQ is a Chicago-based healthcare technology company that builds a cloud platform for systematically collecting, measuring, and analyzing patient-reported outcomes (PROs). Founded in 2016 by Matthew Gitelis, the company connects hospitals, health systems, private practices, and medical device makers on a single EHR-integrated system that turns outcomes data into actionable clinical and operational intelligence. PatientIQ has grown to serve more than 200 healthcare organizations and has collected outcomes data from over 1.4 million patients.
Steve Herne is the CEO of Unlearn.AI, a San Francisco-based company building AI-powered digital twin technology to transform how clinical trials are designed and run. With over 25 years of experience across pharmaceutical R&D companies including WCG, Bioclinica, and Covance, Herne joined Unlearn in May 2024 as Chief Commercial Officer before ascending to CEO in September 2024. Under his leadership, Unlearn — backed by $130M+ in venture funding including a $50M Series C led by Altimeter Capital — is pivoting from research-led to commercially-driven product delivery, with its digital twin models now EMA-qualified and adopted by major biopharma companies to reduce placebo arm sizes by up to 38% in pivotal trials.